Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker RIGL · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) NCT05308264 · Low Risk Myelodysplastic Syndromes R906289 Monosodium (R289 Na) | RIGL Rigel Pharmaceuticals | Phase 1/2 | Recruiting | 86 | Dec 2027 | Registry ↗ |
| Sep 1, 2026 | Study of Olutasidenib and Temozolomide in HGG NCT06161974 · High Grade Glioma, Astrocytoma Olutasidenib + TMZ | RIGL Rigel Pharmaceuticals | Phase 2 | Recruiting | 60 | Jun 2029 | Registry ↗ |
| Aug 11, 2026 | Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies NCT07486713 · AML (Acute Myeloid Leukemia), Glioma Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3… | RIGL Rigel Pharmaceuticals | Phase 4 | Recruiting | 16 | Apr 30, 2027 | Registry ↗ |
| Aug 10, 2026 | Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors NCT07704658 · NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer Pralsetinib, CYP3A4, CYP2C8, and CYP2C9 substrates, and hor… | RIGL Rigel Pharmaceuticals | Phase 4 | Recruiting | 12 | Jul 30, 2027 | Registry ↗ |
| Mar 15, 2024 | Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocyt… NCT04904276 · ITP, Immune Thrombocytopenia Fostamatinib | RIGL Rigel Pharmaceuticals | — | Terminated | 16 | Nov 17, 2022 | Registry ↗ |
| Dec 11, 2023 | Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (IT… NCT02077192 · Immune Thrombocytopenic Purpura Fostamatinib Disodium | RIGL Rigel Pharmaceuticals | Phase 3 | Completed | 123 | Jun 2, 2020 | Registry ↗ |
| Aug 18, 2023 | Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy a… NCT04629703 · Covid19, SARS (Severe Acute Respiratory Syndrome) Fostamatinib, Placebo | RIGL Rigel Pharmaceuticals | Phase 3 | Completed | 280 | Sep 5, 2022 | Registry ↗ |
| May 25, 2023 | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodi… NCT03764618 · Warm Antibody Autoimmune Hemolytic Anemia Fostamatinib disodium, Placebo | RIGL Rigel Pharmaceuticals | Phase 3 | Completed | 90 | Apr 11, 2022 | Registry ↗ |
| Mar 17, 2022 | A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Aut… NCT04138927 · Warm Antibody Autoimmune Hemolytic Anemia Fostamatinib disodium | RIGL Rigel Pharmaceuticals | Phase 3 | Enrolling by invitation | 90 | Apr 2024 | Registry ↗ |
| Jul 21, 2021 | A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemi… NCT02612558 · Warm Antibody Autoimmune Hemolytic Anemia Fostamatinib 150 mg bid | RIGL Rigel Pharmaceuticals | Phase 2 | Completed | 26 | Dec 2019 | Registry ↗ |
| Jun 27, 2019 | Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy NCT02112838 · IGA Nephropathy Fostamatinib 150 mg, Fostamatinib 100 mg | RIGL Rigel Pharmaceuticals | Phase 2 | Completed | 76 | Mar 23, 2018 | Registry ↗ |
| Feb 12, 2019 | A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopen… NCT02076399 · Immune Thrombocytopenic Purpura Fostamatinib disodium, Placebo | RIGL Rigel Pharmaceuticals | Phase 3 | Completed | 76 | Apr 21, 2016 | Registry ↗ |
| Jan 25, 2019 | A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocy… NCT02076412 · Immune Thrombocytopenic Purpura Fostamatinib Disodium, Placebo | RIGL Rigel Pharmaceuticals | Phase 3 | Completed | 74 | Aug 2016 | Registry ↗ |
| Aug 1, 2018 | Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP NCT03363334 · Immune Thrombocytopenic Purpura Fostamatinib disodium 100 mg, Fostamatinib disodium 150 mg | RIGL Rigel Pharmaceuticals | — | No longer available | — | — | Registry ↗ |
| May 1, 2017 | Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3) NCT00665626 · Rheumatoid Arthritis Fostamatinib disodium (R935788), Placebo | RIGL Rigel Pharmaceuticals | Phase 2 | Completed | 219 | Jun 2009 | Registry ↗ |
| Oct 10, 2016 | Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Diseas… NCT02040623 · Chronic Graft-versus-host Disease R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0… | RIGL Rigel Pharmaceuticals | Phase 2 | Completed | 35 | Jul 2016 | Registry ↗ |
| Oct 3, 2016 | To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctiv… NCT01900249 · Keratoconjunctivitis Sicca R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0… | RIGL Rigel Pharmaceuticals | Phase 2 | Completed | 204 | Jul 2014 | Registry ↗ |
| Sep 29, 2016 | A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma NCT01591044 · Asthma Placebo, R940343 1mg | RIGL Rigel Pharmaceuticals | Phase 2 | Completed | 301 | Jul 2013 | Registry ↗ |
| Sep 19, 2016 | Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma NCT00798096 · T Cell Lymphoma Fostamatinib Disodium | RIGL Rigel Pharmaceuticals | Phase 2 | Completed | 18 | Apr 2010 | Registry ↗ |
| Sep 19, 2016 | Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma NCT00446095 · Lymphoma fostamatinib | RIGL Rigel Pharmaceuticals | Phase 1/2 | Completed | 81 | Apr 2010 | Registry ↗ |
| Sep 16, 2016 | Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis NCT00665925 · Rheumatoid Arthritis Fostamatinib disodium (R935788), Fostamatinib disodium (R93… | RIGL Rigel Pharmaceuticals | Phase 2 | Completed | 457 | Jun 2009 | Registry ↗ |
| Jul 14, 2016 | Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic… NCT01597050 · Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic R932333, Placebo | RIGL Rigel Pharmaceuticals | Phase 2 | Completed | 54 | Sep 2013 | Registry ↗ |
| Jun 3, 2016 | Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocy… NCT00706342 · Purpura, Thrombocytopenic, Idiopathic Fostamatinib Disodium / R935788 | RIGL Rigel Pharmaceuticals | Phase 2 | Completed | 18 | Apr 2010 | Registry ↗ |
| Oct 23, 2015 | Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy NCT02433236 · IGA Nephropathy Fostamatinib Disodium tablet 100 mg, Fostamatinib Disodium… | RIGL Rigel Pharmaceuticals | Phase 2 | Withdrawn | 0 | Sep 2015 | Registry ↗ |
24 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:58 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances